Egalet announced that results from a Category 3 oral human abuse potential (HAP) study and a Category 3 intranasal HAP...
Egalet Corporation has announced the company has submitted a new drug application (NDA) for Arymo ER (morphine sulfate) extended-release tablets...
Unmet patient needs in MS management
High-efficacy therapies